Pay in 4 interest-free payments of $6.93 Learn more
Ships within 48 hours · Estimated delivery Aug 27 - Sep 1
The views and opinions expressed in this article are those of the author and do not necessarily reflect the views or positions of the Novo Nordisk Foundation
The GLP-1 diabetes treatment drugs market is expected to grow at a 25.3% CAGR between 2025 and 2035
This case illustrates the intersection of benefits and reality: Medicaid began covering an expensive drug (under pharmacy benefit) with hope of future savings, only to confront immediate budget strain
Mounjaro (tirzepatide) uniquely targets both GLP-1 and GIP receptors, potentially offering more substantial weight reduction and improved glycemic control compared to other GLP-1RAs that only target the GLP-1 receptor, such as Ozempic (semaglutide)
This personalized approach can benefit individuals who dont respond well to standard treatments or have specific medical conditions requiring adjustments
.jpg)
